Literature DB >> 22315442

Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.

Douglas Van Nostrand1, Gauri R Khorjekar, Jeff O'Neil, Shari Moreau, Frank B Atkins, Pejman Kharazi, Mihriye Mete, Shyam P Chennupati, Kenneth D Burman, Leonard Wartofsky.   

Abstract

UNLABELLED: Various studies have compared the detection of functioning residual thyroid tissue after thyroidectomy using radioiodine whole-body (WB) imaging following preparation of patients with injections of recombinant human thyroid-stimulating hormone (rhTSH) and thyroid hormone withdrawal (THW). However, metastases may have radiopharmacokinetics different from normal thyroid tissue. The objective of this study was to evaluate these 2 methods of patient preparation for the detection of metastases from differentiated thyroid cancer (DTC) using (131)I WB imaging and (124)I PET.
METHODS: A prospective study approved by the institutional review board was conducted at Washington Hospital Center from 2006 to 2010 recruiting patients who had DTC, were suspected of having metastasis from DTC (e.g., elevated thyroglobulin level without thyroglobulin antibodies, positive results on recent fine-needle aspiration, suspected enlarging mass, and abnormal findings suggesting metastasis on a diagnostic study) and were referred for (131)I WB dosimetry. All patients subsequently underwent both (131)I WB imaging and (124)I PET performed using the same preparation. All foci of uptake identified on these scans were categorized in a masked manner by consensus of 2 physicians in the following manner: 1, definite physiologic uptake or artifact; 2, most likely physiologic uptake or artifact; 3, indeterminate; 4, most likely locoregional metastases in the neck bed; 5, most likely distant metastases; or 6, definite distant metastases. Foci categorized as 4, 5, and 6 were considered positive for functioning metastases.
RESULTS: Of 40 patients evaluated, 24 patients were prepared with rhTSH and 16 with THW. No statistical difference was noted between the 2 groups for any of the parameters evaluated, including serum thyroglobulin. The percentages of patients with positive foci detected on the rhTSH (131)I and THW (131)I WB scans were 4% (1/24) and 63% (10/16), respectively (P < 0.02). The number of foci detected on the rhTSH (131)I and THW (131)I WB scans were 2 and 58, respectively (P < 0.05). When (124)I PET was used for imaging, the percentages of patients with foci detected on the rhTSH and THW scans were 29% (7/24) and 63% (10/16), respectively (P < 0.03). The number of foci detected on the rhTSH and THW scans were 17 and 117, respectively (P < 0.03).
CONCLUSION: Significantly more foci of metastases of DTC may be identified in patients prepared with THW than in patients prepared with rhTSH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315442     DOI: 10.2967/jnumed.111.096016

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

Review 1.  Radioiodine treatment of well-differentiated thyroid cancer.

Authors:  Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2012-06-26       Impact factor: 3.633

Review 2.  Improving external beam radiotherapy by combination with internal irradiation.

Authors:  A Dietrich; L Koi; K Zöphel; W Sihver; J Kotzerke; M Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-03-18       Impact factor: 3.039

3.  Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer.

Authors:  Donika Plyku; Robert F Hobbs; Kevin Huang; Frank Atkins; Carlos Garcia; George Sgouros; Douglas Van Nostrand
Journal:  J Nucl Med       Date:  2017-01-19       Impact factor: 10.057

4.  The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.

Authors:  Hongxiu Luo; Andrew Tobey; Sungyoung Auh; Craig Cochran; Marina Zemskova; James Reynolds; Cristiane Lima; Kenneth Burman; Leonard Wartofsky; Monica Skarulis; Electron Kebebew; Joanna Klubo-Gwiezdzinska
Journal:  Clin Endocrinol (Oxf)       Date:  2018-08-13       Impact factor: 3.478

Review 5.  PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art.

Authors:  Arnoldo Piccardo; Pierpaolo Trimboli; Luca Foppiani; Giorgio Treglia; Giulia Ferrarazzo; Michela Massollo; Gianluca Bottoni; Luca Giovanella
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

6.  Recombinant human thyrotropin versus thyroid hormone withdrawal in differentiated thyroid carcinoma follow-up: a single center experience.

Authors:  M Sahin; B I Aydoğan; E Özkan; R Emral; S Güllü; M F Erdogan; D Çorapçıoğlu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

7.  ¹²⁴I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy ¹³¹I SPECT/CT.

Authors:  Cecile de Pont; Servais Halders; Jan Bucerius; Felix Mottaghy; Boudewijn Brans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

Review 8.  Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

Review 9.  Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.

Authors:  Einat Slonimsky; Mark Tulchinsky
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

10.  Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal.

Authors:  Hsi-Chen Tsai; Kung-Chu Ho; Shih-Hsin Chen; Jing-Ren Tseng; Lan-Yan Yang; Kun-Ju Lin; Ju-Chin Cheng; Miaw-Jene Liou
Journal:  Diagnostics (Basel)       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.